Advertisement

L'Endocrinologo

, Volume 19, Issue 2, pp 75–78 | Cite as

Abaloparatide

  • Salvatore Minisola
  • Chiara Sonato
  • Veronica Cecchetti
  • Evelina Vigna
  • Vittoria Danese
  • Luciano Colangelo
Rassegna
  • 45 Downloads

Sommario

Il trattamento farmacologico dell’osteoporosi si basa sui farmaci che inibiscono la distruzione ossea oppure su quelli che stimolano la formazione scheletrica. L’abaloparatide è un farmaco anabolizzante, costituito da un analogo sintetico del PTHrP. Gli studi clinici fino ad ora condotti hanno evidenziato la capacità di questa sostanza di ridurre l’incidenza, rispetto al placebo, delle fratture vertebrali, non vertebrali, delle fratture cliniche e delle principali fratture osteoporotiche. Questo farmaco si aggiunge quindi all’armamentario terapeutico del gruppo dei farmaci anabolizzanti fino ad ora rappresentato solo dal PTH 1–34.

Parole chiave

Osteoporosi Fratture Densità minerale ossea Marker del turnover Abaloparatide 

Notes

Conflitto di interesse

Gli autori Salvatore Minisola, Chiara Sonato, Veronica Cecchetti, Evelina Vigna, Vittoria Danese e Luciano Colangelo dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2018_417_MOESM1_ESM.doc (30 kb)
(DOC 31 kB)
40619_2018_417_MOESM2_ESM.doc (30 kb)
(DOC 30 kB)

Bibliografia

  1. 1.
    Minisola S, Cipriani C, Occhiuto M, Pepe J (2017) New anabolic therapies for osteoporosis. Int Emerg Med 12(7):915–921 CrossRefGoogle Scholar
  2. 2.
    Kanis JA, Cooper C, Rizzoli R et al., the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28(7):2023–2034 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Minisola S, Pepe J, Piemonte S, Cipriani C (2015) The diagnosis and management of hypercalcaemia. BMJ 350:h2723 CrossRefPubMedGoogle Scholar
  4. 4.
    Hattersley G, Dean T, Corbin BA et al. (2016) Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling. Endocrinology 157(1):141–149 CrossRefPubMedGoogle Scholar
  5. 5.
    Chew CK, Clarke BL (2017) Abaloparatide: recombinant human PTHrP (1–34) anabolic therapy for osteoporosis. Maturitas 97:53–60 CrossRefPubMedGoogle Scholar
  6. 6.
    Leder BZ, O’Dea LS, Zanchetta JR et al. (2015) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100(2):697–706 CrossRefPubMedGoogle Scholar
  7. 7.
    Miller PD, Hattersley G, Riis BJ et al., the ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722–733 CrossRefPubMedGoogle Scholar
  8. 8.
    Cosman F, Hattersley G, Hu MY et al. (2017) Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res 32(1):17–23 CrossRefPubMedGoogle Scholar
  9. 9.
    McCloskey EV, Johansson H, Oden A et al. (2017) The effect of abaloparatide-sc on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res 32(8):1625–1631 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Moreira CA, Fitzpatrick LA, Wang Y, Recker RR (2017) Effects of abaloparatide-sc (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone 97:314–319 CrossRefPubMedGoogle Scholar
  11. 11.
    Cosman F, Miller PD, Williams GC et al. (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc 92(2):200–210 CrossRefPubMedGoogle Scholar
  12. 12.
    Mazziotti G, Formenti AM, Adler RA et al. (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine 54(3):603–611 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Salvatore Minisola
    • 1
  • Chiara Sonato
    • 1
  • Veronica Cecchetti
    • 1
  • Evelina Vigna
    • 1
  • Vittoria Danese
    • 1
  • Luciano Colangelo
    • 1
  1. 1.Dipartimento di Medicina Interna e Specialità Mediche“Sapienza” Università di RomaRomaItalia

Personalised recommendations